INT107386

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 37
Total Number 37
Disease Relevance 35.94
Pain Relevance 5.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (AGTR1) signal transducer activity (AGTR1)
Anatomy Link Frequency
macrophage 2
Heart 2
blood 1
stroma 1
plasma 1
AGTR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 751 99.80 Very High Very High Very High
antagonist 117 99.28 Very High Very High Very High
Inflammatory mediators 36 97.76 Very High Very High Very High
cINOD 34 97.48 Very High Very High Very High
Inflammatory response 24 95.60 Very High Very High Very High
tolerance 14 94.88 High High
agonist 107 93.96 High High
chemokine 43 93.68 High High
cytokine 107 93.08 High High
Migraine 9 92.84 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 811 99.80 Very High Very High Very High
Hypoxia 217 99.58 Very High Very High Very High
Proteinuria 40 99.52 Very High Very High Very High
Cancer 918 99.50 Very High Very High Very High
Hypertension 130 99.38 Very High Very High Very High
Papillomavirus Infection 72 99.24 Very High Very High Very High
Reprotox - General 1 21 99.16 Very High Very High Very High
Age-related Macular Degeneration 186 99.12 Very High Very High Very High
Neurodegenerative Disease 17 99.08 Very High Very High Very High
Migraine Disorders 2 99.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Blocking these pathways through inhibition of AT1 using one of the commercially available AT1 inhibitors, whilst lifting the induced protective effect of immunosuppression and further reducing inflammation with the use of NSAIDs will both inhibit tumour progression and allow currently developed immunotherapies, such as cancer vaccines, to promote their therapeutic effect uninhibited.
Negative_regulation (inhibition) of AT1 associated with inflammation, cancer and cinod
1) Confidence 0.55 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 1.50 Pain Relevance 0.49
To this effect, AT1 blockade has been hypothesised as the mechanism to overcome cancer associated complications in organ graft recipients [45].
Negative_regulation (blockade) of AT1 associated with cancer
2) Confidence 0.55 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 1.80 Pain Relevance 0.13
While speculative, it is intriguing to consider the possibility that more directed pharmacologic therapy might derive from findings like these; for example, blockade of the AT1R with angiotensin receptor blockade might be especially beneficial in these patients [17].
Negative_regulation (blockade) of angiotensin receptor
3) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2650781 Disease Relevance 0.99 Pain Relevance 0
While speculative, it is intriguing to consider the possibility that more directed pharmacologic therapy might derive from findings like these; for example, blockade of the AT1R with angiotensin receptor blockade might be especially beneficial in these patients [17].
Negative_regulation (blockade) of AT1R
4) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2650781 Disease Relevance 0.98 Pain Relevance 0
AT1 receptor blockade should, in addition, provide a treatment to alleviate the damage caused by bacterial and viral infections, where their destructive action is through chronic inflammation.
Negative_regulation (blockade) of AT1 receptor associated with inflammation and viral infection
5) Confidence 0.40 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 1.60 Pain Relevance 0.35
Given the importance of the immune suppressant effect of inflammation in cancer, it is anticipated that AT1 blockade should also serve to elicit a more effective immune response to other invaders that seek to corrupt the wound recovery process.
Negative_regulation (blockade) of AT1 associated with inflammation, cancer and injury
6) Confidence 0.40 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 1.40 Pain Relevance 0.27
Note the glucocorticoid inhibition of AT1 pro-inflammatory activities via NF?
Negative_regulation (inhibition) of AT1 associated with inflammation
7) Confidence 0.40 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 1.13 Pain Relevance 0.40
Based on current literature and clinical studies on angiotensin receptor inhibitors, the paper concludes that blockade of the AT1 receptor in synergy with cancer vaccines and anti-inflammatory agents should offer a therapy to regress most, if not all, solid tumours.
Negative_regulation (blockade) of AT1 receptor associated with inflammation, cancer and solid tumor
8) Confidence 0.40 Published 2004 Journal J Inflamm (Lond) Section Abstract Doc Link PMC1074345 Disease Relevance 2.04 Pain Relevance 0.28
Although still at a theoretical stage, this evidence leads to the formulation of the hypothesis that effective blockade of AT1 with a tight binding receptor antagonist, in combination with NSAIDs to further control the inflammation, and immunotherapy, such as cancer vaccines, would provide an effective treatment.
Negative_regulation (blockade) of AT1 associated with inflammation, cancer, antagonist and cinod
9) Confidence 0.40 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 1.09 Pain Relevance 0.34
In contrast, AT1 inhibitors have been shown to inhibit the proliferation of prostate cancer cells stimulated with EGF or angiotensin II, through the suppression of MAPK or STAT3 phosphorylation [57].
Negative_regulation (inhibitors) of AT1 associated with reprotox - general 1
10) Confidence 0.40 Published 2004 Journal J Inflamm (Lond) Section Body Doc Link PMC1074345 Disease Relevance 0.77 Pain Relevance 0.06
Conversely, as resulting from studies with candesartan and irbesartan, there is no evidence that AT1 blockade reduces the primary outcome of morbidity and mortality in patients with chronic heart failure and preserved ejection fraction, although a modest benefit with candesartan may be observed in terms of fewer hospitalization for heart failure.


Negative_regulation (blockade) of AT1 in heart associated with myocardial infarction
11) Confidence 0.32 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788599 Disease Relevance 0.79 Pain Relevance 0
The above scenario depicts a strong rationale for the specific and selective blockade of AT1 receptors through specific drugs.
Negative_regulation (blockade) of AT1
12) Confidence 0.32 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788599 Disease Relevance 0.50 Pain Relevance 0.07
Effects like this could contribute to the adverse effects reported in Congestive Heart Failure patients taking a combinatorial therapy including AT1R blockers and ?
Negative_regulation (blockers) of AT1R in Heart associated with heart rate under development
13) Confidence 0.29 Published 2010 Journal J Mol Signal Section Body Doc Link PMC2954983 Disease Relevance 0.10 Pain Relevance 0.12
The ARB which exert their antihypertensive effect through specific blockade of the angiotensin II via blockade of the angiotensin subtype 1 receptor appears to have a much lower incidence of recurrent angioedema.
Negative_regulation (blockade) of angiotensin subtype 1 receptor associated with pressure and volume under development
14) Confidence 0.29 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2919521 Disease Relevance 2.43 Pain Relevance 0.03
AT1 blockade with candesartan
Negative_regulation (blockade) of AT1
15) Confidence 0.18 Published 2008 Journal PPAR Research Section Body Doc Link PMC2396446 Disease Relevance 1.32 Pain Relevance 0.14
These antitumor properties are also demonstrated by a number of sartans, selective Ang II AT1-receptor antagonists [94-101], further reinforcing that blockade of AT1R could be an effective anticancer strategy, not only because these drugs target cancer cells, but also endothelial cells at the tumor and stroma.
Negative_regulation (blockade) of AT1R in stroma associated with cancer and antagonist
16) Confidence 0.17 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2615789 Disease Relevance 1.21 Pain Relevance 0.14
Interestingly, AT1-receptor blockade with Losartan inhibited LDL oxidation and macrophage cholesterol biosynthesis (Keidar et al 1999), and attenuated atherosclerosis in E0 mice (Keidar et al 1997).
Negative_regulation (blockade) of AT1 in macrophage associated with atherosclerosis
17) Confidence 0.14 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515419 Disease Relevance 0.10 Pain Relevance 0.08
All these findings suggest a possible role for AT1-receptor blockade in reducing LDL-peroxidation.
Negative_regulation (blockade) of AT1
18) Confidence 0.14 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515419 Disease Relevance 0.76 Pain Relevance 0.10
Interestingly, all these effects could be reduced by AT1-receptor blockade with losartan.
Negative_regulation (blockade) of AT1
19) Confidence 0.14 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515419 Disease Relevance 0.63 Pain Relevance 0.06
[Adverse effects of angiotensin II type 1 receptor blockers ].
Negative_regulation (blockers) of angiotensin II type 1 receptor
20) Confidence 0.14 Published 2002 Journal Kardiologiia Section Title Doc Link 12494195 Disease Relevance 0.65 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox